Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIOPEN High-Risk Neuroblastoma Study 2
NL-OMON52860Phase 3Recruiting
- Sponsor
- Gustave Roussy
- Start
- Mar 2021
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of busulfan, melphalan, thiotepa, irinotecan, temozolomide and 1 more in neuroblastoma (7 arms), sponsored by Gustave Roussy. Started Mar 2021; status: recruiting.
02
Drugs
busulfanmelphalanthiotepairinotecantemozolomide
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NL-OMON52860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52860.